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Summary The prognostic role of epidermal growth factor receptor (EGFR) remains controversial in patients with lung cancer. Previous
assays for EGFR have primarily been qualitative or, at best, semiquantitative. In the present study, using fresh-frozen tissue from 190
unselected lung cancer patients, quantification of EGFR (EGFREW) using a recently developed enzyme-linked immunosorbent assay
(ELISA) technique was compared with results (EGFRd) obtained using immunohistochemistry (IHC). Correlation between results obtained
by the two different techniques was highly significant (r5 = 0.63, P < 0.001, n = 190). This correlation improved even further (r5 = 0.76) when
sections were estimated using an IHC score that took into account percentage staining, intensity and relative tumour area. Furthermore, the
relationship between clinicopathological features and prognosis was identical for the two methods. The expression of EGFR was highest in
squamous cell carcinomas, but it was not correlated with other characteristcs such as age, sex, histological grading, stage or prognosis. We
conclude that evaluation of EGFR content using IHC and ELISA produces comparable results.
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Epidermal growth factor receptor (EGFR) is the protein product of
the proto-oncogene HER-I. Ligand binding to the extracellular
region of EGFR causes receptor dimerization. resultin, in
autophosphorvlation and activation ofcytoplasmic signal protein.
which ultimateiy triggers DNA synthesis associated with prolifer-
ation and differentiation (Prigent and Lemoine. 1992). However.
whether aberrant expression of EGFR is causally or consequently
related to the development of cancer remains to be established.
Some studies have reported EGFR to be ofprognostic importance
in lung cancer (Volm and Mattern. 1993. Volm et al. 1993): unfor-
tunately. the relationship to sun-ival has been inconsistent (Pfeiffer
et al. 1996a).
Immunohistochemistry (IHC) is the most widely applied tech-
nique to assess expression ofEGFR in patients with non-small-cell
lung cancer (NSCLC) (Pfeiffer et al. 1996a). Immuno-
histochemical results depend on the pnmary antibody. the visual-
ization system and whether fixed or frozen tissues are used.
Furthermore. the evaluation of immunohistochemical slides is
inherently qualitative or. at best. semiquantitative. The enzyme-
linked immunosorbent assay (ELISA) can quantify EGFR in
cytosol extracts. We used a recently developed ELISA technique
(Christensen et al. 1995) to measure the level of EGFR in a large
cohort of lung cancer patients and compared the results w-ith
immunohistochemical analysis on crvosections and with clinical
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and pathological data. To our knowledge. this is the first study to
compare the detection ofEGFR using, IHC and ELISA.
MATERIAL AND METHODS
Patients and tumour samples
Frozen tumour tissue from 190 previousl1 untreated lung cancer
patients (median age 61 years (range 42-79 vears): 131 men and
59 women) were available for ELISA and IHC. All the patients
were surgically treated at Odense Unixersit) Hospital. Denmark.
between 1984 and 1991: median follow-up was 66 months (range
39-119 months). The study wvas approved by the local ethics
committee.
We analysed the relationship betxx een EGFR and histological
subtype and the correlation betw-een IHC and ELISA for all lung
cancer patients: howexer. all other analyses were restricted to 180
patients with NSCLC. The TNM stage ofNSCLC was determined
retrospectively. according, to the new International Staging System
for lung, cancer (Mountain. 1987). No patient received post-opera-
tive adjuvant cytotoxic or radiation therapy.
Tissue preparation
Lung resections were received unfixed in the patholog laboratory.
immediately after surgical remoxal. One piece oftumour measuring
approximately 1 cm" was cut out and divided in two. One part was
placed in crvoconservation tubes. snap-frozen at -80'C. and stored
until further examinations. The other part was formalin frxed and
embedded in paraffin forhistological classification.
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Figure 1 (A) Measurement of EGFR content using EUSA (EGFRELsA) in
190 patients with lung cancer. (B) Estimation of EGFR content using IHC
(EGFR,,c) in 190 patients with lung cancer
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Biopsies were stored at -80'C until further analysis. We used a
recently developed ELISA technique to measure EGFR content
(EGFRE,,,5) (Christensen et al. 1995). Briefly, biopsies (median
44 mg; range 5-192 mg) from 190 patients were cut. ultrasonical-
lyhomogenized in buffer and centrifuged at 20 000g. The
membrane pellet was resuspended in buffer and the receptor was
solubilized by incubation with 2% Triton X-100. followed by
centrifugation at 20 000g. EGFR was measured in the super-
natant. We used EGFR1 (RPN 513; Amersham, UK) as catching
antibody and biotinylated Ab-1 (GRO1: Oncogene Science. USA)
as detecting antibody. EGFR from placenta membranes was used
as the calibration standard. The detection limit was 0.08 nmol I'.
Immunohistochemical analysis
EGFR immunostaining was performed on 5-gm cryostat sections.
using the peroxidase labelled Streptavidin-Biotin (LSAB) tech-
nique and EGFR1 (Amersham. UK) as primary antibody (Pfeiffer
et al. 1996a. b).
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Figure 2 (A) Correlation between EGFR, and EGFR,sA in 190 patients
with lung cancer (r = 0.63, P < 0.001). (B) Correlaton between an IHC score
(immunohistocherical score combining intensity, number of stained tumour
cells and relative tumour area) and EGFRBsA (r = 0.76; P < 0.0001).
(A) r = 0.63; (B) rs= 0.76
Immunohistochemical assessment
The percentage of positively reacting tumour cells (EGFR.:
(-100%) was estimated by one author (PP) (Pfeiffer et al. 1996a).
An immunohistochemical score (IHC score). which took into
account percentage staining. intensity and relative tumour area, was
also calculated. The average intensity of staining (INTsc0) was
given a score between 0 and 3. The number of positively stained
tumour cells (CELLsco) was also scored between 0 and 3: 0: 1
(1-49%): 2 (50-79%): 3 (80-100%). In addition, the relative
tumour area was assessed by evaluating the proportion of malig-
nant cells compared with the entire histological section(AREAso)
and expressed as a proportion (0-1.0). The IHC score was then
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Table 1 Relationship between EGFRsjs, content and histobgical s%type
in 190 patients with lung cancer.
EGFRJ cosint
LOW MedIum High
n ( (%) (%)
SqC 100 37 27 36
AdC 57 74 10 16
LaC 23 61 22 17
Carcinoid 9 100 0 0
SCLC 1 100 0 0
Total 190 54 20 26
NSCLC > SCLC + carcinoid, P < 0.001; SqC > AdC, P < 0.00001;
SqC > LaC, P= 0.01. EGFRE,,,, EGFR content measured using EUSA
SqC, squamous ceUcarcrran AdC, adenocardnrma LaC, lrge cell
caranoma T, pnmary tumour, N, lymp node.
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protein) was arbitrarily chosen (Figure IA). The patients were thus
categorized as low (< 1.0 nmol EGFR g' protein), medium
(1.0-2.0 nmol EGFR g' protein) or high (> 2.0 nmol EGFR g-'
protein).
The distribution ofEGFR.,, is shown in Figure iB; the median
EGFRH,c was 80%. EGFRELLsA and EGFR, results of paired
samples from 190 patients with lung cancer are shown in Figure
2A. There was a highly significant correlation between EGFRI
and EGFREJ,,A (r = 0.63, P < 0.001). The association between
ELISA and IHC was improved even further (rs = 0.76) when the
IHC score was used, i.e. when we also took into account the inten-
sity ofstaining and relative tumour area (Figure 2B).
The association between EGFR expression and other variables
was similarwhetherwe usedresults obtained using ELISAor IHC.
We foundexpressionofEGFR in all subtypes ofNSCLC, but most
frequently in squamous cell carcinomas (Table 1).
EGFRalSA orEGFRu was notcorrelated with age, tumoursize,
T status, lymph node involvement, stage, histological grading or
time ofdiagnosis. Furthermore, squamous cell carcinoma was the
only variable that correlated with EGFR expression in a logistic
regression model. The relative risk for high EGFP.ESA and
EGFR, content for squamous cell carcinoma was 4.1 (95% CI
2.2-7.7) and 4.4 (95% CI 2.3-8.3), respectively.
We did not find any correlation between EGFR expression and
survival in the entire group ofpatients with NSCLC (Figure 3), nor
in any subgroup analysis.
DISCUSSION
m--------- Most studies on NSCLC have focussed on the protein level. Berger
et al (1987) found a close correlation between LHC and auto-
Z ffi * t - _ |. phophhorylation activity. Ligand-binding studies have shown that
0 1 2 3 4 5 6 7 8 EGFR-binding characteristics were comparable in tumour and
Folow-u time (years) normal lung tissue (Hwang et al, 1986; Veale et al, 1989; Dittadi
3 Survil of 180patients with NSCLC according to m urement et al, 1991). These studies point to the fact that, if expressed
R using EUSA (low, mebum orhigh) (P=0.6). low n =8- - -, in NSCLC, a normal functional EGFR is operating. Thus, this
n n=42;-, high n = 49 receptorcan be detected by antibodiesthatrecognize EGFR, using
either ELISA or IHC.
It is often stated thatpatients withoverexpression ofEGFR have
ed to each tumour by multiplying INTsco, CELLsco and a shorter survival, but in a prior study (Pfeiffer et al, 1996a) we
sco; the IHC score thus ranged from 0 to 9.0. were unable to find acorrelation between EGFR andprognosis. To
substantiate these findings, we measured EGFR content in frozen
tical evaluation tumour samples using a recently developed ELISA technique
(Christensen et al, 1995). We found ahighly significantcorrelation
values are from two-sided tests. Statistical significance was betweenEGFR,, andEGFREmA, and also an identical correlation
d for P-values less than orequal to 0.05. Relative risk (RR) with othervariables. Ahigh EGFRP,EA valuealwayscorresponded
owed by 95% confidence intervals (CI). The association with ahighEGFRw value, whereas samples with ahigh EGFRI,
en two variables was quantified using Spearman's rank showed variable values forEGFRazA. To interpret this discrep-
Ltion coefficient(rs) tesL ancy, one must realize that even althoughEGFRELISA is a quantita-
vival curves were estimated according to the Kaplan-Meier tive measure, ELISA calculates an average EGFR content in a
d (Kaplan and Meier, 1958) and compared using the log- homogenized tissue sampleconsisting oftumour tissue intermixed
-st (Peto et al, 1977) or, if there were three or more ordered with various amounts ofnon-tumourtissue, including normal lung
ries, the log-rank test for trend. BMDP/PC Release 7.01 tissue, connective tissue and necrotic tissue. Another inconve-
P Statistical Software, 1993, Los Angeles, CA, USA) was nience is that it requires handling of fresh or frozen tissue. The
Dr all statistical analyses. major advantages ofELISA are its quantitative nature and the use
ofa calibration curve (Christensen et al, 1995).
JLTS Quantitation ofEGFR has been reported in a few prior studies.
Veale et al (1993) measured EGFR using the ligand-binding assay
edian EGFREJA was 1.0 nmol EGFR g-' protein (range in 19 selected patients with NSCLC. They found that EGFR quan-
.9nmol EGFR g- protein). This value was selected as a titation may give prognostic information and proposed confirma-
f point and a second cut-off point (2.0 nmol EGFR g-' tion in a larger prospective study. Recent studies have shown that
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EGFR content can be quantitated on tumour sections (Stanton et
al, 1994; Robertson et al, 1996), but whether quantitative analysis
will add to the prognostic significance of EGFR is doubtful.
Furthermore, it is still complex to interpret results in hetero-
geneous tumours, i.e. what is the biological importance of a large
amount of EGFR in few tumour cells compared with a lower
amount in most tumourcells.
IHC represents a small sectional view ofa larger tissue area; the
result relies very much on the immunohistochemical technique,
and the results are subjective and qualitative. The majoradvantage
of the immunohistochemical technique is the maintenance of
tissue architecture and in situ localization of the antigen. By
contrast with ELISA, in which cancer cells cannot be distin-
guished from non-malignant tissue, this distinction can easily be
made using immunohistochemical analysis. Also, IHC is able to
identify tumour positivity, even in very small tumour samples.
When we took into account the percentage of stained tumour
cells, intensity of staining and cellularity, the correlation between
ELISA and IHC was further improved. At least some of the
remaining discrepancy may be due to intrumoral heterogeneity.
To our knowledge, a detailed comparison of EGFR expression
using ELISA andIHC has not beenpublishedpreviously, but some
studies have determined the related growth factor receptor
pl851ER-2 using NHC and ELISA (Dawkins et al, 1993; Dittadi et
al, 1993; Nugent et al, 1994; Piffanelli et al, 1996). In brief, the
overall agreement was comparable with that ofthe present study.
In agreement with most other studies, we found expression of
EGFR (EGFRa5A or EGFRJ) in all subtypes of NSCLC, but
most frequently in squamous cell carcinomas, and no correlation
between EGFR expression and the size of the primary tumour,
lymph node status or stage. The expression of EGFR without
correlation to stage suggests an important stepduring early tumour
genesis. It might provide the potential tumour cell with the ability
continually to proliferate when the supply of growth factors is
restricted and/or escape terminal differentiation.
In conclusion, detection of EGFR using IHC and ELISA
produces comparable results, particularly when IHC is estimated
using an immunohistochemical score that evaluates percentage
stining, intensity and relative tumour area, however further
methodological standardization is needed. Expression of EGFR
was found in all histological subtypes ofNSCLC, butespecially in
squamous cell carcinoma. Quantitative or qualitative EGFR
expression was not correlated with extension of tumour tissue or
histological grading and was without prognostic value in patients
with NSCLC.
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